Form 4: Sage Therapeutics Executive Reports Routine RSU Vesting and Tax Withholding
Insider Transaction Report
A recent SEC Form 4 filing reveals that Gregory L. Shiferman, Senior Vice President, General Counsel and Secretary of Sage Therapeutics, Inc., engaged in a routine transaction involving the vesting of restricted stock units and subsequent share withholding for tax obligations.
Summary
- Gregory L. Shiferman, Senior Vice President, General Counsel and Secretary of Sage Therapeutics, Inc. (SAGE), filed a Form 4 detailing a transaction on June 24, 2025.
- The transaction involved the vesting of 234 time-based restricted stock units (RSUs) that were granted on October 28, 2021, under the company's 2014 Stock Option and Incentive Plan.
- These RSUs vested 25% on September 24, 2022, and continue to vest quarterly thereafter in twelve equal installments.
- As part of this vesting, 79 shares of common stock were disposed of at a price of $9.22 per share to satisfy tax withholding obligations.
- Following this transaction, Mr. Shiferman beneficially owns 30,950 shares of Sage Therapeutics common stock.
Sentiment
Score: 5
Explanation: The document is a routine compliance filing detailing an executive's RSU vesting and tax withholding, which is a neutral event with no significant positive or negative implications for the company's operations or financial performance.
Positives
- The vesting of restricted stock units (RSUs) indicates the continued retention and incentivization of key executive personnel, aligning their interests with shareholder value.
- The transaction is a routine part of executive compensation plans, reflecting the successful progression of previously granted equity awards.
Negatives
- No negative information was disclosed in this routine compliance filing.
Risks
- No specific risks were identified or discussed in this Form 4 filing.
Future Outlook
The document indicates that the remaining restricted stock units will continue to vest quarterly in twelve equal installments, following the initial 25% vesting on September 24, 2022.
Industry Context
This Form 4 filing is a standard disclosure for insider transactions, common across all publicly traded companies. The vesting of restricted stock units and subsequent share withholding for tax purposes is a routine event in executive compensation programs, particularly in the biotechnology and pharmaceutical sectors where equity-based incentives are prevalent. It reflects the ongoing administration of long-term incentive plans designed to align executive interests with shareholder returns.
Comparison to Industry Standards
- This is a routine insider transaction filing (Form 4) related to executive compensation. There are no specific comparable companies, projects, or results to list as the filing simply reports a personal stock transaction by an executive. Such transactions are standard practice across all industries for executives receiving equity compensation.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Delegation of Authority | The filing includes a Power of Attorney (POA) dated November 1, 2024, granted by Gregory L. Shiferman. This POA authorizes Chris Benecchi (Chief Operating Officer), Brandon Marsh (Senior Director, Corporate Counsel), and Stuart Falber of WilmerHale to prepare and sign SEC Forms 4, 5, and 144 on his behalf, demonstrating a standard corporate governance practice for managing executive compliance with securities regulations. | 2024-11-01 | Enhances efficiency and ensures timely compliance with SEC reporting requirements for executive stock transactions. |
Stakeholder Impact
- Shareholders: Minimal direct impact, as this is a routine compensation-related transaction. It confirms the ongoing incentivization of a key executive.
- Employees: No direct impact on general employees.
- Customers: No direct impact.
- Suppliers: No direct impact.
- Creditors: No direct impact.
Next Steps
- Continued quarterly vesting of Gregory L. Shiferman's remaining restricted stock units.
Key Dates
| Date | Description |
|---|---|
| 2021-10-28 | Grant date of time-based restricted stock units (RSUs) to Gregory L. Shiferman. |
| 2022-09-24 | First vesting date (25%) of the restricted stock units. |
| 2024-11-01 | Date of Power of Attorney granted by Gregory L. Shiferman. |
| 2025-06-24 | Transaction date for RSU vesting and shares withheld for tax obligations. |
| 2025-06-26 | Date the Form 4 was signed and filed. |
Keywords
Sage Therapeutics, SAGE, SEC Form 4, Insider Trading, Restricted Stock Units, RSU Vesting, Tax Withholding, Executive Compensation, Corporate Governance, Gregory L. Shiferman
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.